|
WO2020150545A1
|
|
Pyrazole derivatives as modulators of the wnt/b-catenin signaling pathway
|
|
WO2020150552A2
|
|
Methods of treating cartilage disorders through inhibition of clk and dyrk
|
|
EP3813826A1
|
|
Methods of treating cancer using a clk inhibitor
|
|
US2019382402A1
|
|
Indazole containing macrocycles and therapeutic uses thereof
|
|
KR20200126393A
|
|
5-heteroaryl substituted indazole-3-carboxamide and preparation and use thereof
|
|
WO2019089835A1
|
|
Diazanaphthalen-3-yl carboxamides and preparation and use thereof
|
|
WO2019084497A1
|
|
6-(6-membered heteroaryl & aryl)isoquinolin-3-yl carboxamides and preparation and use thereof
|
|
US2019125741A1
|
|
6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
|
|
WO2019079626A1
|
|
6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
|
|
WO2018085865A1
|
|
Single-dose, ready-to-use injectable formulations
|
|
CA3041291A1
|
|
Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
|
|
SG10201912248RA
|
|
Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
|
|
CN109311819A
|
|
Isoquinolin -3- base benzamide type and its preparation and its purposes
|
|
AR108325A1
|
|
ISOQUINOLIN-3-IL CARBOXAMIDS AND PREPARATION AND USE OF THE SAME
|
|
CA3004297A1
|
|
2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
|
|
US2018214428A1
|
|
3-(1h-indol-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
|
US2018222891A1
|
|
3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
|
|
US2018228781A1
|
|
3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
|
WO2017023988A1
|
|
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017024021A1
|
|
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
